Background

Elevated triglyceride levels are a risk factor for cardiovascular disease. Angiopoietin-like protein 4 (Angptl4) is a metabolic factor that raises plasma triglyceride levels by inhibiting lipoprotein lipase (LPL). In non-diabetic individuals, the ANGPTL4 coding variant E40K has been associated with lower plasma triglyceride levels while the T266M variant has been associated with more modest effects on triglyceride metabolism. The objective of this study was to determine whether ANGPTL4 E40K and T266M are associated with triglyceride levels in the setting of obesity and T2D, and whether modification of triglyceride levels by these genetic variants is altered by a lifestyle intervention designed to treat T2D.

Methods

The association of ANGPTL4 E40K and T266M with fasting triglyceride levels was investigated in 2,601 participants from the Look AHEAD Clinical Trial, all of whom had T2D and were at least overweight. Further, we tested for an interaction between genotype and treatment effects on triglyceride levels.

Conclusions

This is the first study to demonstrate that the ANGPTL4 E40K and T266M variants are associated with lower triglyceride levels in the setting of T2D. In addition, our findings demonstrate that ANGPTL4 genotype status does not alter triglyceride response to a lifestyle intervention in the Look AHEAD study.

Studies in large Western [1] and Asian [2] population cohorts have demonstrated an independent association between elevated triglyceride levels and cardiovascular disease (CVD) risk. Triglyceride levels may become elevated through independent effects caused by the metabolic syndrome and type 2 diabetes (T2D), both well-established risk factors for CVD [3]. Furthermore, lifestyle changes can significantly reduce triglyceride levels [4] and may moderate the risk of CVD [5].

Lipoprotein lipase (LPL) regulates triglyceride levels by hydrolyzing the triglyceride component of circulating lipoproteins [6, 7]. At least some of the effects of T2D on triglycerides are mediated by LPL, whose expression and activity is influenced by insulin [6, 7]. The angiopoietin-like protein 4 (Angptl4) peptide, which is primarily expressed in the liver and white adipose tissue [8], is another well established regulator of LPL activity and triglyceride levels. In vitro studies confirm that Angptl4, acting as an oligomer, inhibits enzymatic hydrolysis of triglycerides by preventing LPL dimerization [9]. ANGPTL4 has two common coding SNPs: E40K and T266M. The E40K substitution prevents Angptl4 oligomer formation, which leads to reduced Angptl4 mediated inhibition of LPL activity [10]. To date, results in over 30,000 individuals from non-diabetic [11] and population-based [12] studies have confirmed that the E40K loss-of-function variant is associated with significantly lower triglyceride levels [11, 12]. In contrast, the ANGPTL4 T266M cSNP, which is more prevalent than E40K, has been shown to have a smaller effect on triglyceride levels in non-diabetic populations [12].

Given the importance of triglycerides and CVD risk in the context of T2D we sought to determine whether the ANGPTL4 E40K and T266M polymorphisms are associated with triglyceride levels in well characterized patients with T2D participating in the Look AHEAD study. Second, we asked whether the ANGPTL4 variants modified the triglyceride response to an intensive lifestyle intervention designed to treat T2D that was randomly assigned to Look AHEAD participants. Finding an association of ANGPTL4 variants with triglyceride levels in T2D, particularly if modifiable by a lifestyle intervention, would have important implications for personalized approaches to the treatment of T2D and cardiovascular disease.

Look AHEAD (Action for Health in Diabetes)

Look AHEAD is a multicenter clinical trial examining whether an intensive lifestyle intervention (ILI) aimed at weight loss and increased activity will reduce cardiovascular disease in T2D compared with diabetes support and education (DSE). The Look AHEAD multi-ethnic cohort is comprised of 5,145 male and female participants who have T2D, aged 45-76 years, and with a body mass index (BMI) ≥ 25 kg/m2. Included in our study are samples from Look AHEAD participants who self-identified their race and ethnicity as non-Hispanic White, African American or Hispanic. The design, baseline characteristics, and 1-year interim results have been described in detail [4, 13, 14]. This manuscript is based on a subset of the baseline data set from participants who provided consent for genetic studies and were enrolled from Look AHEAD sites that participated in ancillary studies (see Acknowledgement). 2,601 participants for whom DNA was available for these analyses, were genotyped for ANGPTL4 T266M (rs1044250, 6959 C > T) and E40K (rs116843064, 118 G > A) cSNPs using TaqMan technology (Applied Biosciences). All participants provided written informed consent for DNA collection and genetic studies as part of Look AHEAD. The Tufts Medical Center Institutional Review Board approved the study.

Statistical Methods

Statistical analyses were performed using Intercooled Stata 10.2 for Windows (StataCorp LP, Texas, USA). A χ2 test compared whether the observed frequencies conformed to Hardy-Weinberg equilibrium (HWE). A general additive model of inheritance, or dominant model in the case of E40K, was used to assess the association between genotype and clinical endpoints. All clinical data were log transformed to approximate a normal distribution before analysis. Multivariate linear regressions were used for baseline association analyses, controlling for known and significant confounders including: age, gender, study site, BMI, smoking, statins, diuretics, diabetes drugs, insulin, other lipid drugs, alcohol, menopause, and hormone replacement therapy (HRT) use. Using a dominant model there was 80% power to detect a 0.08 mmol/L difference in triglycerides between E40K allele carriers and non-carriers at baseline. Using an additive model there was 80% power to detect a difference at baseline of 0.02 mmol/L in triglyceride levels per T266M allele. Both power calculations are based on a 2-sided test at 5% significance level.

Multivariate linear regression was also utilized to determine interaction of DSE and ILI with E40K and T266M genotype. Additional association analyses performed at the 1-year follow-up time point were adjusted for age, gender, study site and the baseline measure of the dependent variable. P values < 0.05 were considered significant. Linkage disequilibrium (LD) between sites was estimated using Haploview (http://www.broad.mit.edu/mpg/haploview) version 3.0.

ANGPTL4: effects on plasma Triglyceride and HDL levels in Look AHEAD

Baseline characteristics of the Look AHEAD study participants included in these analyses, separated by ethnic groups, are shown in Table 1. Of the 2,601 study participants, 1,424 are taking lipid lowering medication. ANGPTL4 genotype frequences are shown in Table 2. All genotype distributions were in HWE. No LD was observed between E40K and T266M in non-Hispanic White Americans (D' = 1.00 and r2 = 0.05). The MAF for the E40K and T266M variants did not differ significantly between non-Hispanic Whites and Hispanics. The MAF of the E40K SNP in African Americans by comparison was very low (MAF 0.001).

Table 1

Baseline Data in Look AHEAD Genetic cohort by ethnic group

Variable

Non-Hispanic white Americans

African American

Hispanics

Pvalue*

n

Mean

95% CI

N

Mean

95% CI

n

Mean

95% CI

Female (%)

2023

50.2

-

436

76.6

-

142

64.8

-

Insulin Use (%)

2023

17.0

-

436

22.9

-

142

19.7

-

Statin Use (%)

2023

50.1

-

436

37.6

-

142

38.0

-

Metabolic Syndrome (%)

2023

95.4

-

436

76.6

-

142

64.8

-

Hypertension (%)

2023

84.9

-

436

89.5

-

142

81.0

-

Age (years)

2023

59.47

(59.17, 59.77)

436

58.40

(57.97, 58.83)

142

57.32

(56.46, 58.19)

< 0.001

HbA1c (%)

2023

7.17

(7.12, 7.21)

436

7.34

(7.27, 7.41)

142

7.52

(7.38, 7.66)

< 0.001

Weight (lbs)

2023

223.85

(222.28, 255.44)

436

220.83

(218.54, 223.14)

142

217.85

(213.36, 222.43)

0.021

BMI (kg/m2)

2023

35.88

(35.65, 36.11)

436

35.93

(35.58, 36.29)

142

35.99

(35.29, 36.70)

0.790

Waist circumference (cm)

2020

114.98

(114.42, 115.55)

436

113.17

(112.34, 114.00)

142

111.38

(109.77, 113.01)

< 0.001

Triglyceride (mmol/L)

2023

1.87

(1.82, 019)

436

1.57

(1.52, 1.62)

142

1.32

(1.23, 1.41)

< 0.001

LDL-cholesterol (mmol/L)

1975

2.77

(2.74, 2.80)

427

2.80

(2.75, 2.86)

138

2.84

(2.73, 2.94)

0.269

HDL-cholesterol (mmol/L)

1975

1.06

(1.05, 1.07)

427

1.11

(1.09, 1.13)

138

1.16

(1.13, 1.20)

< 0.001

Cholesterol (mmol/L)

1975

4.85

(4.81, 4.89)

427

4.81

(4.75, 4.87)

138

4.77

(4.66, 4.89)

0.242

Fasting Glucose (mmol/L)

1975

8.32

(8.22, 8.42)

427

8.09

(7.95, 8.24)

138

7.88

(7.60, 8.16)

0.007

SBP (mm/Hg)

1993

128.82

(128.06, 129.58)

432

129.52

(128.39, 130.66)

140

130.23

(127.98, 132.52)

0.268

DBP (mm/Hg)

1993

69.41

(69.03, 69.80)

432

70.98

(70.4, 71.57)

140

72.59

(71.41, 73.79)

< 0.001

Data presented is mean (95% confidence intervals), adjusted for age and gender;* overall comparison between the three ethnic groups after adjustment for gender.

Table 2

Look AHEAD genotype frequencies of ANGPTL4 E40K and T266M by ethnic group

After adjustment for covariates, the E40K variant was significantly associated with baseline plasma triglyceride levels in non-Hispanic White Look AHEAD participants (Table 3). Individuals who were K40 carriers had mean ± SD triglyceride levels of 1.61 ± 0.62 mmol/L, 0.33 mmol/L lower than E40 homozygotes (p = 0.001). A significant association of the T266M and triglyceride levels was also observed (Table 4). Individuals homozygous for the M266 allele had triglyceride levels of 1.75 ± 0.58 mmol/L, 0.24 mmol/L lower than T266 homozygotes (p = 0.002). The association of E40K and T266M with triglyceride levels remained significant in those individuals not taking a lipid lowering medication (Tables 3 and 4, respectively). The association of E40K with triglyceride levels was also significant in subjects taking lipid lowering drugs, while the triglyceride association with T266M was not found in the setting of lipid lowering therapy (data not shown).

We examined whether the association of T266M with triglyceride levels merely reflected the presence of E40K or whether the effect was also observed independently. When the K40 carriers were excluded, the association of T266M with triglycerides remained significant in multivariate linear regression using an additive model of inheritance, with M266 homozygotes having 0.25 mmol/L lower triglycerides compared to TT individuals (p = 0.002) (Table 4).

Next, we analyzed participants by composite E40K and T266M genotypes. We found a significant genotype dosage effect in which the addition of K40 to M266 was associated with lower triglyceride levels suggesting an additive effect in the Look AHEAD cohort (Figure 1). Homozygous M266 carriers that were also heterozygous K40 carriers had the lowest triglyceride levels.

We were unable to test an association of E40K and triglycerides in African American and Hispanic Look AHEAD participants due to the low number of genotype carriers (Additional File 1: Supplemental Tables 1 and 2).

One year follow-up data in non-Hispanic white Americans

Look AHEAD participants in this genetic sub-cohort randomly assigned to DSE achieved a 1% reduction of BMI compared with an 11% reduction in the ILI group (p < 0.001). The response to DSE and ILI in the Look AHEAD participants taking part in these genetic studies was similar to the one-year differences observed in the full cohort [4]. Triglyceride levels decreased in both randomisation groups, with subjects in the ILI group achieving 27% lower levels compared with 9% lower levels in the DSE group. Tests for interaction between intervention and E40K and T266M status were not statistically significant (p = 0.416 and 0.202 respectively). The absolute changes in triglyceride levels were similar between E40K and T266M genotypes (Additional File 1: Supplemental Tables 3 and 4).

In this study, we demonstrate for the first time that ANGPTL4 E40K and T266M are associated with triglyceride levels in the setting of T2D. This finding is significant because elevated triglyceride levels found in E40 homozygotes and T266 carriers may contribute to an increased risk of CVD in the setting of T2D. Non-Hispanic White Look AHEAD K40 carriers had 17% lower triglyceride levels than non-K40 carriers, which is a similar effect as reported in studies in the general population [11, 12]. We therefore conclude that the effect of the ANGPTL4 E40K polymorphism is unlikely diminished to any substantial degree by the independent effects of obesity and T2D on triglyceride levels. The lack of interaction with treatment indicates that there is no differential effect of genotypes on triglycerides depending upon randomization to ILI versus DSE. This final point demonstrates the potential role of a life-style intervention to reduce triglyceride levels conferred by genetic background [15].

We identified an association of triglyceride levels with ANGPTL4 T266M that appeared to be independent of, and potentially additive with, the E40K variant. The T266M triglyceride effect is consistent with the European Atherosclerosis Research Study II CHD offspring study which demonstrated that M266 homozygotes had enhanced triglyceride clearance following an oral fat tolerance test [12]. Our results contrast to the findings of Talmud et al [12], who reported a similar pattern of linkage disequilibrium between the two cSNPs, but found the association of T266M with triglycerides to be dependent on the K40 allele. The observation that the triglyceride-lowering effect of T266M is not lost after removal of K40 carriers in Look AHEAD suggests that the T266M cSNP may have an independent effect on triglycerides in the setting of T2D. The fact that the association of T266M with triglyceride levels was not observed in Look AHEAD participants receiving lipid lowering medication, but maintained on those not on medications, suggests that an important interaction between medications and T266M may exist. Alternatively, the reduced sample size in this sub-group analysis may have reduced our power to detect an association.

E40K carriers in ARIC and the Copenhagen City Heart Study had significantly higher HDL-cholesterol levels than non-carriers, while the Dallas Heart Study did not confirm this relationship [11]. While a mechanistic link between plasma triglycerides and HDL-cholesterol mediated by the cholesterol ester transfer protein is well established [16], large differences in triglycerides are typically required before a significant change in HDL-cholesterol is found. We detected a modest, albeit non-significant, elevation of HDL-cholesterol in K40 carriers. Other factors that regulate HDL-cholesterol levels (e.g. insulin resistance, obesity) may have weakened the effect of E40K.

Both the E40 (within the N-terminus) and the T266 (within the C-terminus) amino acid residues are conserved across human, mouse and rat species [17] suggesting functional importance. Formation of Angptl4 oligomers by disulphide bonds in the coiled-coil N-terminus [17] is required for inhibition of LPL activity. The E40K substitution destabilizes the protein after secretion, preventing the extracellular accumulation of oligomers and abolishing the ability of the Angptl4 protein to inhibit LPL activity [10]. By comparison, the mechanism by which T266M alters the function of the C-terminal fibrinogen domain remains undefined. Romeo et al [18] has demonstrated that non-synonymous mutations throughout ANGPTL4, including the fibrinogen domain, compromise the ability of Angptl4 to inhibit LPL activity.

A limitation of the study is the low number of African American and Hispanic ANGPTL4 variant carriers. Statistically this resulted in underpowered association studies which prevented the examination of E40K in African Americans. The ANGPTL4 variant frequencies for Hispanics were comparable to Non-Hispanic White Americans (0.027 and 0.021). The low total number of Hispanics (n = 137) and E40K carriers (n = 6) reduced our power to detect an association. While we included anti-diabetic medication use as a covariate in our analyses an additional limitation is that we were unable to control for the effect of specific anti-diabetic medications and doses, which may have an effect on triglyceride levels.

In conclusion, we demonstrate for the first time an association of the ANGPTL4 coding variants with triglyceride levels in the setting of T2D. Further, our results suggest that the triglyceride response to a lifestyle intervention is not altered by ANGPTL4 genotype status. This finding broadens our understanding of the role of Angptl4 in regulation of LPL metabolism of triglycerides. The independent association of T266M with triglycerides has broad implications because this polymorphism has a high frequency in the general population.

Acknowledgements and Funding

We gratefully acknowledge the contributions of the Look AHEAD Study Group members [4]. This study is supported by the National Institutes of Health (R01 DK072497), the British Heart Foundation (PG2005/014) and additional sources listed below. This manuscript is based on a subset of the baseline data set from participants enrolled from the Look AHEAD sites at Pennington Biomedical Research Center; Massachusetts General Hospital; University of Colorado Health Sciences Center; Baylor College of Medicine; The University of Tennessee Health Science Center, University of Tennessee; University of Minnesota; St. Luke's Roosevelt Hospital Center; University of Pennsylvania; University of Pittsburgh; and Brown University. Additional support was received from the Massachusetts General Hospital Mallinckrodt General Clinical Research Center (M01-RR-01066); the University of Colorado Health Sciences Center General Clinical Research Center (M01 RR00051) and Clinical Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR00211-40); the University of Pittsburgh General Clinical Research Center (M01 RR000056 44) and NIH grant (DK 046204). Author AKH was supported by the Training Program in Cardiovascular Research (NIH, 5T32HL069770) and MCS is supported by a Unilever/BBSRC Case studentship.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MCS participated in all aspects of this project including molecular genetic studies, association analysis and manuscript preparation; AKH and IP advised association analysis and manuscript preparation; MCM and JAC carried out molecular genetic studies; AK, JM, AB, HJP, and DMN assisted in data interpretation and edited/reviewed the manuscript; PJT proposed and advised the study and edited/reviewed the manuscript; GSH participated in all aspects of the project including study design, molecular genetic studies, statistical analysis, and manuscript preparation. All authors read and approved the final manuscript.

Pre-publication history

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.